Osteosarcoma in a Patient Receiving Long-Term TNF Inhibitor Therapy.
Patients with inflammatory bowel disease (IBD) have an increased risk of developing malignancy. The use of immunosuppressive therapies and tumour necrosis factor (TNF) inhibitors in these patients may provide a further risk for the development of malignancy. We report the clinical and pathological findings of a high grade osteosarcoma in a patient with Crohns disease receiving TNF inhibitor therapy. In this case, a 32-year old female presented with a painful right knee after receiving maintenance adalimumab for Crohns disease for a period of six years. There is a substantial hypothetical link between TNF inhibitor regimens such as adalimumab and an increased risk of malignancy. TNF inhibitor therapy should be ceased and chemotherapy and surgery is an effective combined modality approach in these patients. The role of TNF inhibitors in patients after cancer diagnosis is uncertain and further research is required to assess efficacy and safety.
Medical Oncology Department, Mater Misericordiae University Hospital, Dublin 7.
J
J
Greene
Medical Oncology Department, Mater Misericordiae University Hospital, Dublin 7.
G M
GM
O'Kane
Medical Oncology Department, Mater Misericordiae University Hospital, Dublin 7.
D N
DN
Carney
Medical Oncology Department, Mater Misericordiae University Hospital, Dublin 7.
E
E
Aherne
Medical Oncology Department, Mater Misericordiae University Hospital, Dublin 7.
G C
GC
O'Toole